Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lapatinib Ditosylate

FDA-approved product (tablet, oral), marketed as Lapatinib Ditosylate, Tykerb.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lapatinib Ditosylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • HER2 Positive Breast Carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Human epidermal growth factor receptor 2 (her2) tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lapatinib Ditosylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lapatinib Ditosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Implantable Microdevice In Primary Brain Tumors

    NCT04135807 · start 2020-03-03

    Registered record
    Registry ID
    NCT04135807
    Conditions
    Grade II Glioma; Grade III Glioma; Grade IV Glioma; Astrocytoma; Oligodendroglioma of Brain; Anaplastic Astrocytoma of Brain; Anaplastic Oligodendroglioma; Glioblastoma
    Interventions
    Microdevice
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2020-03-03
    Completion
    2028-06-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGrade II Glioma; Grade III Glioma; Grade IV Glioma; Astrocytoma +4 more
    InterventionMicrodevice
    PhaseEarly phase 1
    Registry statusRecruiting

  • Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

    NCT04850625 · start 2020-01-15

    Registered record
    Registry ID
    NCT04850625
    Conditions
    Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-15
    Completion
    2021-06-15
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

    NCT03262935 · start 2017-12-15

    Registered record
    Registry ID
    NCT03262935
    Conditions
    Metastatic Breast Cancer
    Interventions
    (vic-)trastuzumab duocarmazine; Physician's choice
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-15
    Completion
    2022-06-30
    Enrolment
    437

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    Intervention(vic-)trastuzumab duocarmazine; Physician's choice
    PhasePhase 3
    Registry statusCompleted

  • Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

    NCT03080805 · start 2017-05-03

    Registered record
    Registry ID
    NCT03080805
    Conditions
    HER2 Positive Metastatic Breast Cancer
    Interventions
    Pyrotinib Plus Capecitabine; Lapatinib Plus Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-05-03
    Completion
    2021-03
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2 Positive Metastatic Breast Cancer
    InterventionPyrotinib Plus Capecitabine; Lapatinib Plus Capecitabine
    PhasePhase 3
    Registry statusUnknown

  • Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

    NCT02836847 · start 2016-07

    Registered record
    Registry ID
    NCT02836847
    Conditions
    Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer
    Interventions
    biological test; GEMOX; Cetuximab; Trastuzumab; Gefitinib; Lapatinib; Everolimus; Sorafenib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-07
    Completion
    2020-12
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer
    Interventionbiological test; GEMOX; Cetuximab; Trastuzumab +5 more
    PhasePhase 2
    Registry statusUnknown

  • A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

    NCT02422199 · start 2015-05

    Registered record
    Registry ID
    NCT02422199
    Conditions
    HER2 Positive Metastatic Breast Cancer
    Interventions
    pyrotinib; Lapatinib; capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2015-05
    Completion
    2018-12
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2 Positive Metastatic Breast Cancer
    Interventionpyrotinib; Lapatinib; capecitabine
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer

    NCT02342587 · start 2014-12-03

    Registered record
    Registry ID
    NCT02342587
    Conditions
    HER2-positive Refractory Advanced Cancer
    Interventions
    Lapatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-12-03
    Completion
    2016-08-21
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-positive Refractory Advanced Cancer
    InterventionLapatinib
    PhasePhase 2
    Registry statusCompleted

  • Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

    NCT02029001 · start 2014-03

    Registered record
    Registry ID
    NCT02029001
    Conditions
    Malignant Solid Neoplasms
    Interventions
    Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD); Olaparib (300 mg BID); Durvalumab + Tremelimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2014-03
    Completion
    2028-10
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Solid Neoplasms
    InterventionNilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD) +3 more
    PhasePhase 2
    Registry statusRecruiting

  • Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

    NCT01873833 · start 2013-07-29

    Registered record
    Registry ID
    NCT01873833
    Conditions
    HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
    Interventions
    capecitabine; cyclophosphamide; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-07-29
    Completion
    2021-03-02
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
    Interventioncapecitabine; cyclophosphamide; lapatinib ditosylate; trastuzumab +1 more
    PhasePhase 2
    Registry statusTerminated

  • A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

    NCT01808573 · start 2013-03-29

    Registered record
    Registry ID
    NCT01808573
    Conditions
    HER2+ Metastatic Breast Cancer (MBC)
    Interventions
    neratinib; capecitabine; lapatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03-29
    Completion
    2019-12-09
    Enrolment
    621

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2+ Metastatic Breast Cancer (MBC)
    Interventionneratinib; capecitabine; lapatinib
    PhasePhase 3
    Registry statusCompleted

  • A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

    NCT01771458 · start 2012-10

    Registered record
    Registry ID
    NCT01771458
    Conditions
    Reccurent/Metastatic Solid Tumor Disease
    Interventions
    Targeted therapy based on molecular profiling : Imatinib; Tumor biopsy; Standard Chemotherapy; Targeted therapy based on molecular profiling : Everolimus; Targeted therapy based on molecular profiling : Vemurafenib; Targeted therapy based on molecular profiling : Sorafenib; Targeted therapy based on molecular profiling : Erlotinib; Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab; Targeted therapy based on molecular profiling : Dasatinib; Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication); Targeted therapy based on molecular profiling : Abiraterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-10
    Completion
    2016-12
    Enrolment
    742

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionReccurent/Metastatic Solid Tumor Disease
    InterventionTargeted therapy based on molecular profiling : Imatinib; Tumor biopsy; Standard Chemotherapy; Targeted therapy based on molecular profiling : Everolimus +7 more
    PhasePhase 2
    Registry statusCompleted

  • Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

    NCT02015169 · start 2012-07-09

    Registered record
    Registry ID
    NCT02015169
    Conditions
    HER2-positive Gastric Cancer Patients With Liver Metastasis
    Interventions
    Lapatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-07-09
    Completion
    2017-11-17
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-positive Gastric Cancer Patients With Liver Metastasis
    InterventionLapatinib
    PhasePhase 2
    Registry statusCompleted

  • Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

    NCT01612351 · start 2012-06

    Registered record
    Registry ID
    NCT01612351
    Conditions
    Head and Neck Cancer; Squamous Cell Carcinoma of the Head and Neck
    Interventions
    Carboplatin; Paclitaxel; Lapatinib; Cisplatin; Cisplatin; Ipsilateral Radiation; Bilateral Radiation; Transoral Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-06
    Completion
    2025-05-19
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer; Squamous Cell Carcinoma of the Head and Neck
    InterventionCarboplatin; Paclitaxel; Lapatinib; Cisplatin +4 more
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)

    NCT01534455 · start 2012-02

    Registered record
    Registry ID
    NCT01534455
    Conditions
    Metastatic Breast Cancer
    Interventions
    Lapatinib + 1,23 mg Eribulin; Lapatinib + 1,76 mg Eribulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-02
    Completion
    2015-03
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionLapatinib + 1,23 mg Eribulin; Lapatinib + 1,76 mg Eribulin
    PhasePhase 2
    Registry statusTerminated

  • Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

    NCT00999804 · start 2011-10

    Registered record
    Registry ID
    NCT00999804
    Conditions
    Breast Cancer
    Interventions
    Lapatinib; Letrozole; Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2011-10
    Completion
    2026-01
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionLapatinib; Letrozole; Trastuzumab
    PhasePhase 2
    Registry statusActive not recruiting